Trial Profile
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs CDX-3379 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics
- Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals
- 03 Jan 2023 Results of pooled analysis of three studies (NCT00779389, NCT01218048, NCT02473731) assessing response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit, published in the Clinical Cancer Research.
- 15 Jul 2019 Results published in the Clinical Cancer Research
- 10 May 2018 Results presented in the Celldex Therapeutics Inc media release.